Abstract
-
An estimated 8,490 new cases of Hodgkin’s lymphoma were diagnosed in the USA in 2010.
-
Reed–Sternberg cells are the malignant cells in classical Hodgkin’s lymphoma (CD15+, CD30+, and CD45−). In nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL), these cells express B-cell markers (CD20+, CD79a+, and CD45+) and are CD15− and CD30−.
-
Common presentation is an asymptomatic lymph node enlargement in supradiaphragmatic areas (neck, mediastinum). Approximately 70% will have stage I or II disease.
-
For early-stage disease, the standard approach is a combined modality with short-course chemotherapy (ABVD: Adriamycin, bleomycin, vinblastine, dacarbazine), followed by moderate-dose radiation targeting involved lymph node region(s). When subdivided into favorable and unfavorable groups, 5-year disease-free survival rates of approximately 90–95% (favorable) and 85–90% (unfavorable) are expected, respectively.
-
The majority of patients with NLPHL present at an early stage and have excellent prognoses with radiation alone.
-
For advanced-stage disease, chemotherapy is the main modality, and the focus recently has been on intensifying chemotherapy to improve efficacy. When a complete response has been obtained with ABVD chemotherapy or its equivalent, there is no role for consolidation radiation therapy. Overall 5-year diseasefree survival is 60–85%.
-
High-dose therapy with autologous stem cell transplant is the salvage therapy of choice for refractory patients or for those who relapse after a short initial remission from chemotherapy.
-
Different types of radiation fields have been used in Hodgkin’s lymphoma and involved-field radiation therapy (IFRT) is the current standard. It covers involved lymph nodes before chemotherapy and the nodal region (wholly or partially) in which the involved lymph node(s) is/are located.
-
The radiation doses used in combined-modality protocols are well within the tolerance of normal tissues in virtually all supradiaphragmatic areas.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bernard, M., Tsang, R. (2011). Hodgkin’s Lymphoma. In: Lu, J., Brady, L. (eds) Decision Making in Radiation Oncology. Medical Radiology(), vol 0. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16333-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-16333-3_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-16332-6
Online ISBN: 978-3-642-16333-3
eBook Packages: MedicineMedicine (R0)